Delving into the Latest Updates on Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

主要目的：评价MBT-1316 片在健康受试者中单次给药的安全性和耐受性，评价MBT-1316 片在健康受试者中多次给药的安全性和耐受性；次要目的：评价MBT-1316 片在健康受试者中单次给药的药代动力学特征，评价MBT-1316 片在健康受试者中多次给药的药代动力学特征，评价食物对MBT-1316 片药代动力学的影响以及探索MBT-1316 药物代谢转化特征。

[Translation]

Primary purpose: To evaluate the safety and tolerability of MBT-1316 tablets after single administration in healthy subjects, and to evaluate the safety and tolerability of MBT-1316 tablets after multiple administration in healthy subjects; Secondary purpose: To evaluate the pharmacokinetic characteristics of MBT-1316 tablets after single administration in healthy subjects, and to evaluate the pharmacokinetic characteristics of MBT-1316 tablets after multiple administration in healthy subjects, and to evaluate the effect of food on the pharmacokinetics of MBT-1316 tablets, and to explore the drug metabolic transformation characteristics of MBT-1316.

Start Date21 Jul 2023

Sponsor / Collaborator

Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

CTR20223380 / RecruitingPhase 1

评价MBT-1316 片在慢性乙型肝炎患者中多剂量单次、多次给药的安全性、耐受性、药效学、药代动力学特征的Ib 期临床试验

[Translation] Phase Ib clinical trial to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetic characteristics of MBT-1316 tablets in patients with chronic hepatitis B after single and multiple doses

主要目的：评价MBT-1316 片在慢性乙型肝炎患者中单次给药的安全性和耐受性；评价MBT-1316 片在慢性乙型肝炎患者中多次给药的安全性和耐受性。次要目的：评价MBT-1316 片在慢性乙型肝炎患者中多次给药的药效学特征；评价MBT-1316 片在慢性乙型肝炎患者中单次给药的药代动力学特征；评价MBT-1316 片在慢性乙型肝炎患者中多次给药的药代动力学特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of MBT-1316 tablets after single administration in patients with chronic hepatitis B; To evaluate the safety and tolerability of MBT-1316 tablets after multiple administration in patients with chronic hepatitis B. Secondary objective: To evaluate the pharmacodynamic characteristics of MBT-1316 tablets after multiple administration in patients with chronic hepatitis B; To evaluate the pharmacokinetic characteristics of MBT-1316 tablets after single administration in patients with chronic hepatitis B; To evaluate the pharmacokinetic characteristics of MBT-1316 tablets after multiple administration in patients with chronic hepatitis B.

Start Date03 Apr 2023

Sponsor / Collaborator

Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

CTR20222348 / RecruitingPhase 1

评价MBT-1316片在健康受试者中多剂量单次、多次给药的安全性、耐受性、药代动力学特征及食物影响的Ia期临床试验

[Translation] Phase Ia clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and food effects of single and multiple doses of MBT-1316 tablets in healthy subjects

⑴主要目的：评价MBT-1316片在健康受试者中单次给药的安全性和耐受性和评价MBT-1316片在健康受试者中多次给药的安全性和耐受性；⑵次要目的：评价MBT-1316片在健康受试者中单次给药的药代动力学特征、评价MBT-1316片在健康受试者中多次给药的药代动力学特征、评价食物对MBT-1316片药代动力学的影响以及探索MBT-1316药物代谢转化特征。

[Translation]

⑴Main objective: To evaluate the safety and tolerability of a single dose of MBT-1316 tablets in healthy subjects and to evaluate the safety and tolerability of multiple doses of MBT-1316 tablets in healthy subjects; ⑵Secondary objectives: To evaluate the pharmacokinetic characteristics of a single dose of MBT-1316 tablets in healthy subjects, to evaluate the pharmacokinetic characteristics of multiple doses of MBT-1316 tablets in healthy subjects, to evaluate the effect of food on the pharmacokinetics of MBT-1316 tablets, and to explore the drug metabolic transformation characteristics of MBT-1316.

Start Date23 Sep 2022

Sponsor / Collaborator

Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

Phase 1 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MBT-1316	Hepatitis B, Chronic More	Phase 1
HY-1608 ( OOR x μ opioid receptor )	Pain, Postoperative More	IND Approval
MBT-1805 ( PPARδ )	Liver Cirrhosis, Biliary More	Discontinued